AT 501

Drug Profile

AT 501

Alternative Names: AT501; H7N9 influenza vaccine - Medigen Vaccinology; Influenza A virus vaccine H7N9 - Medigen-Vaccinology

Latest Information Update: 03 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Health Research Institutes
  • Developer Medigen Vaccinology Corp
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Influenza A virus H7N9 subtype

Most Recent Events

  • 03 Aug 2017 AT 501 is still in phase-I/II clinical development in Influenza-A virus H7N9 subtype (Prevention, In adults) in Taiwan (Medigen Vaccinology website, August 2017)
  • 01 Feb 2016 Medigen completes phase-I/II clinical trials in Influenza-A virus H7N9 subtype (Prevention, In adults) in Taiwan (Parenteral) (NCT02436928)
  • 01 Apr 2015 Phase-I/II clinical trials in Influenza-A virus H7N9 subtype (Prevention, In adults) in Taiwan (Parenteral) (NCT02436928)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top